Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22860806 | 1.00 | KMT2A (0.61) | KMT2AHTTBACE1ITGA4PKM | |
| SCHEMBL22860756 | 0.87 | KMT2A (0.47) | KMT2AHTTITGA4GAA | |
| SCHEMBL22860776 | 0.84 | KMT2A (0.43) | KMT2AHTTPKMGAA | |
| Limazocic SCHEMBL9326335 | 0.83 | HTT (0.58) | KMT2AHTTITGA4 | |
| Limazocic SCHEMBL1230921 | 0.83 | HTT (0.58) | KMT2AHTTITGA4 | |
| Limazocic SCHEMBL9329801 | 0.83 | HTT (0.58) | KMT2AHTTITGA4 | |
| SCHEMBL22860781 | 0.82 | KMT2A (0.42) | KMT2AHTTGAA | |
| SCHEMBL22860783 | 0.81 | HTT (0.41) | KMT2AHTTITGA4 | |
| SCHEMBL22860767 | 0.81 | HTT (0.41) | KMT2AHTTITGA4 | |
| SCHEMBL22860772 | 0.80 | KMT2A (0.41) | KMT2AHTTITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5082836-A | Autoimmune diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1992-01-21 | — | — | US | claimed |
| US-5041435-A | Treatment of Liver Disorders and Autoimmune Diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1991-08-20 | — | — | US | claimed |
| US-20210000727-A1 | DITHIAZOCANE COMPOUNDS FOR THE COSMETIC USE THEREOF | L'OREAL (FR) | 2021-01-07 | — | — | US | disclosed |
| EP-0356006-B1 | Cyclic sulfur-containing compounds | SANTEN PHARMACEUTICAL CO LTD (JP) | 1994-03-02 | — | — | EP | disclosed |
| US-5128467-A | Immunomodulation, liver disorders | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1992-07-07 | — | — | US | disclosed |
| US-5082836-A | Autoimmune diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1992-01-21 | — | — | US | disclosed |
| US-5041435-A | Treatment of Liver Disorders and Autoimmune Diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1991-08-20 | — | — | US | disclosed |
| EP-0356006-A1 | Cyclic sulfur-containing compounds | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000727-A1 | DITHIAZOCANE COMPOUNDS FOR THE COSMETIC USE THEREOF | KRT18, DSG1, KRTCAP2 | KMT2A 570/4885HTT 2205/4885BACE1 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.